Therapeutic progress I: Current treatment of rheumatoid arthritis
Identifieur interne : 002C60 ( Main/Exploration ); précédent : 002C59; suivant : 002C61Therapeutic progress I: Current treatment of rheumatoid arthritis
Auteurs : N. J. L. Gittoes [Royaume-Uni]Source :
- Journal of Clinical Pharmacy and Therapeutics [ 0269-4727 ] ; 1994-06.
English descriptors
- Teeft :
- Acute phase response, Adverse reactions, Alcohol abuse, Antiinflammatory, Antiinflammatory drugs, Antirheumatic drugs, Arthritis, Azathioprine, Baseline, Baseline value, Blood dyscrasias, Blood levels, Blood pressure, Bone marrow suppression, British journal, Chemotherapeutic agents, Clinical evidence, Clinical practice, Clinical response, Clinical studies, Conventional dmards, Creatinine, Current treatment, Cytotoxic drug, Disease activity, Disease activity index, Disease course, Disease process, Disease severity, Dmard, Dmards, Dos, Drug interactions, Early arthritis, Effective treatment, Efficacy, Erythrocyte sedimentation rate, Fluid retention, Full blood count, Functional capacity, Hydroxychloroquine, Individual patient characteristics, Inflammatory, Inflammatory process, Initial dose, Intramuscular administration, Little effect, Liver function tests, Maintenance dose, Methotrexate, Methylprednisolone acetate, Nonsteroidal, Nonsteroidal antiinflammatory drugs, Nonsteroidal drugs, Nsaid, Nsaid therapy, Occular toxicity, Oral gold, Oral preparation, Other dmards, Parenteral gold, Peptic ulceration, Pincus, Potential role, Progressive disease, Pulmonary hypersensitivity, Radiographic evidence, Radiological progression, Rash, Relative toxicity, Renal, Renal failure, Renal function, Renal impairment, Resistant disease, Rheumatic, Rheumatic diseases, Rheumatic diseuses, Rheumatoid, Rheumatoid arthritis, Rheumatoid factor, Rheumatology, Second line drugs, Short term, Significant improvement, Steroid, Symptomatic relief, Therapeutic approach, Toxic, Toxic drugs, Toxicity, Toxicity index, Treatment duration, Treatment protocol.
Abstract
Over recent years the pharmacological treatment strategy for rheumatoid arthritis (RA) has changed. An early, aggressive approach has been adopted with a view to maintaining functional capacity. The changing role of nonsteroidal antiinflammatory agents is discussed in the light of the potential toxicity of this class of drugs. The current use of second‐line agents is dealt with in depth and includes guidelines to patient monitoring. Particular attention has been paid to the growing use of cyclosporin A in the treatment of RA as this drug represents the newest, most potent, nonexperimental form of treatment. The questions of when to introduce second‐line agents, who should receive treatment and how many drugs should be prescribed are all addressed in this review. The relative efficacy and toxicity of these agents is discussed and a treatment protocol is proposed.
Url:
DOI: 10.1111/j.1365-2710.1994.tb00668.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000218
- to stream Istex, to step Curation: 000218
- to stream Istex, to step Checkpoint: 001A45
- to stream Main, to step Merge: 002D20
- to stream Main, to step Curation: 002C60
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic progress I: Current treatment of rheumatoid arthritis</title><author><name sortKey="Gittoes, N J L" sort="Gittoes, N J L" uniqKey="Gittoes N" first="N. J. L." last="Gittoes">N. J. L. Gittoes</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A4B34F557CC65B368EC5A1A6A506E1FAA86FD18F</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1111/j.1365-2710.1994.tb00668.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-8PKQGHSB-C/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000218</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000218</idno><idno type="wicri:Area/Istex/Curation">000218</idno><idno type="wicri:Area/Istex/Checkpoint">001A45</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001A45</idno><idno type="wicri:doubleKey">0269-4727:1994:Gittoes N:therapeutic:progress:i</idno><idno type="wicri:Area/Main/Merge">002D20</idno><idno type="wicri:Area/Main/Curation">002C60</idno><idno type="wicri:Area/Main/Exploration">002C60</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Therapeutic progress I: Current treatment of rheumatoid arthritis</title><author><name sortKey="Gittoes, N J L" sort="Gittoes, N J L" uniqKey="Gittoes N" first="N. J. L." last="Gittoes">N. J. L. Gittoes</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Medicine, Queen Elizabeth Hospital Birmingham</wicri:regionArea><wicri:noRegion>Queen Elizabeth Hospital Birmingham</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Clinical Pharmacy and Therapeutics</title><title level="j" type="alt">JOURNAL OF CLINICAL PHARMACY THERAPEUTICS</title><idno type="ISSN">0269-4727</idno><idno type="eISSN">1365-2710</idno><imprint><biblScope unit="vol">19</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="147">147</biblScope><biblScope unit="page" to="162">162</biblScope><biblScope unit="page-count">16</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1994-06">1994-06</date></imprint><idno type="ISSN">0269-4727</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0269-4727</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acute phase response</term><term>Adverse reactions</term><term>Alcohol abuse</term><term>Antiinflammatory</term><term>Antiinflammatory drugs</term><term>Antirheumatic drugs</term><term>Arthritis</term><term>Azathioprine</term><term>Baseline</term><term>Baseline value</term><term>Blood dyscrasias</term><term>Blood levels</term><term>Blood pressure</term><term>Bone marrow suppression</term><term>British journal</term><term>Chemotherapeutic agents</term><term>Clinical evidence</term><term>Clinical practice</term><term>Clinical response</term><term>Clinical studies</term><term>Conventional dmards</term><term>Creatinine</term><term>Current treatment</term><term>Cytotoxic drug</term><term>Disease activity</term><term>Disease activity index</term><term>Disease course</term><term>Disease process</term><term>Disease severity</term><term>Dmard</term><term>Dmards</term><term>Dos</term><term>Drug interactions</term><term>Early arthritis</term><term>Effective treatment</term><term>Efficacy</term><term>Erythrocyte sedimentation rate</term><term>Fluid retention</term><term>Full blood count</term><term>Functional capacity</term><term>Hydroxychloroquine</term><term>Individual patient characteristics</term><term>Inflammatory</term><term>Inflammatory process</term><term>Initial dose</term><term>Intramuscular administration</term><term>Little effect</term><term>Liver function tests</term><term>Maintenance dose</term><term>Methotrexate</term><term>Methylprednisolone acetate</term><term>Nonsteroidal</term><term>Nonsteroidal antiinflammatory drugs</term><term>Nonsteroidal drugs</term><term>Nsaid</term><term>Nsaid therapy</term><term>Occular toxicity</term><term>Oral gold</term><term>Oral preparation</term><term>Other dmards</term><term>Parenteral gold</term><term>Peptic ulceration</term><term>Pincus</term><term>Potential role</term><term>Progressive disease</term><term>Pulmonary hypersensitivity</term><term>Radiographic evidence</term><term>Radiological progression</term><term>Rash</term><term>Relative toxicity</term><term>Renal</term><term>Renal failure</term><term>Renal function</term><term>Renal impairment</term><term>Resistant disease</term><term>Rheumatic</term><term>Rheumatic diseases</term><term>Rheumatic diseuses</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid factor</term><term>Rheumatology</term><term>Second line drugs</term><term>Short term</term><term>Significant improvement</term><term>Steroid</term><term>Symptomatic relief</term><term>Therapeutic approach</term><term>Toxic</term><term>Toxic drugs</term><term>Toxicity</term><term>Toxicity index</term><term>Treatment duration</term><term>Treatment protocol</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Over recent years the pharmacological treatment strategy for rheumatoid arthritis (RA) has changed. An early, aggressive approach has been adopted with a view to maintaining functional capacity. The changing role of nonsteroidal antiinflammatory agents is discussed in the light of the potential toxicity of this class of drugs. The current use of second‐line agents is dealt with in depth and includes guidelines to patient monitoring. Particular attention has been paid to the growing use of cyclosporin A in the treatment of RA as this drug represents the newest, most potent, nonexperimental form of treatment. The questions of when to introduce second‐line agents, who should receive treatment and how many drugs should be prescribed are all addressed in this review. The relative efficacy and toxicity of these agents is discussed and a treatment protocol is proposed.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Gittoes, N J L" sort="Gittoes, N J L" uniqKey="Gittoes N" first="N. J. L." last="Gittoes">N. J. L. Gittoes</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C60 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C60 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A4B34F557CC65B368EC5A1A6A506E1FAA86FD18F
|texte= Therapeutic progress I: Current treatment of rheumatoid arthritis
}}
| This area was generated with Dilib version V0.6.33. |  |